Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Head & Neck 1Breast 1

Conditions

Head and Neck Neoplasms 8Neoplasms 4Carcinoma, Squamous Cell 4Squamous Cell Carcinoma of Head and Neck 3Carcinoma 2Skin Neoplasms 1Recurrence 1Neoplasm Metastasis 1Laryngeal Diseases 1Breast Neoplasms 1

Interventions

Cetuximab 14Cisplatin 12pembrolizumab 11Paclitaxel 9Gemcitabine 9durvalumab 6Nivolumab 6Docetaxel 6toripalimab 5Carboplatin 5Radiotherapy 4Fluorouracil 4Cyclophosphamide 4fludarabine 3Valproic Acid 3Capecitabine 3tremelimumab 2spartalizumab 2nimotuzumab 2irinotecan sucrosofate 2fludarabine phosphate 2cemiplimab 2anlotinib 2Sunitinib 2S 1 (combination) 2Radiation 2Oxaliplatin 2NVP-BKM120 2Methotrexate 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Bleomycin × Head & Neck × Clear all
NCT01606566 2022-02-18

A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.

PCI Biotech AS

Phase 2 Terminated
26 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡